1
|
Vendrely V, Ronchin P, Minsat M, Le Malicot K, Lemanski C, Mirabel X, Etienne PL, Lièvre A, Darut-Jouve A, de la Fouchardière C, Giraud N, Breysacher G, Argo-Leignel D, Thimonnier E, Magné N, Abdelghani MB, Lepage C, Aparicio T. Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: Results of the FFCD 0904 phase II trial. Radiother Oncol 2023; 186:109742. [PMID: 37315583 DOI: 10.1016/j.radonc.2023.109742] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2023] [Revised: 05/29/2023] [Accepted: 06/05/2023] [Indexed: 06/16/2023]
Abstract
BACKGROUND AND PURPOSE Standard treatment of squamous cell carcinoma of the anus (SCCA)is 5-fluorouracil (5FU) and mitomycin C (MMC) based chemoradiotherapy (CRT). This phase II study (EudraCT: 2011-005436-26) assessed the tolerance and complete response (CR) rate at 8 weeks of panitumumab (Pmab) combined with MMC-5FU-based CRT. METHODS Patients with locally advanced tumors without metastases (T2 > 3 cm, T3-T4, or N + whatever T stage) were treated with IMRT up to 65 Gy and concomitant CT according to the doses defined by a previous phase I study (MMC: 10 mg/m2; 5FU: 400 mg/m2; Pmab: 3 mg/kg). The expected CR rate was 80%. RESULTS Forty-five patients (male: 9, female: 36; median age: 60.1 [41.5-81]) were enrolled in 15 French centers. The most common related grade 3-4 toxicities observed were digestive (51.1%), hematologic (lymphopenia: 73.4%; neutropenia: 11.1%), radiation dermatitis (13.3%), and asthenia (11.1%) with RT interruption in 14 patients. One patient died because of mesenteric ischemia during the CRT, possibly related to treatment. In ITT analysis, the CR rate at 8 weeks after CRT was 66.7% [90%CI: 53.4-78.2]. Median follow-up was 43.6 months [IC 95%: 38.61-47.01]. Overall survival, recurrence-free and colostomy-free survival at 3 years were 80% [95%CI: 65.1-89], 62.2% [IC95%: 46.5-74.6] and 68.8 % [IC95%: 53.1-80.2] respectively. CONCLUSION Panitumumab in combination with CRT for locally advanced SCCA failed to meet the expected CR rate and exhibited a poor tolerance. Furthermore, late RFS, CFS, and OS did not suggest any outcome improvement to justify further clinical trials. CLINICALTRIALS gov identifier: NCT01581840.
Collapse
Affiliation(s)
- Véronique Vendrely
- Radiation Oncology Department, CHU Bordeaux, Bordeaux, France; BRIC (BoRdeaux Institute of OnCology), UMR1312, INSERM, University of Bordeaux, F-33000 Bordeaux, France.
| | | | | | - Karine Le Malicot
- Fédération Francophone de Cancérologie Digestive, University of Burgundy, Biostatistics, Dijon, France, EPICAD INSERM LNC-UMR 1231, Dijon, France
| | - Claire Lemanski
- Department of Radiation Oncology, Montpellier Cancer Institute (ICM), Montpellier, France
| | - Xavier Mirabel
- Radiotherapy Department, Centre Oscar Lambret, Lille, France
| | | | - Astrid Lièvre
- Gastroenterology Department, Rennes University Hospital, Rennes 1 University, Inserm U1242 COSS (Chemistry Oncogenesis Stress Signaling), Rennes, France
| | | | | | - Nicolas Giraud
- Radiation Oncology Department, CHU Bordeaux, Bordeaux, France
| | | | | | | | - Nicolas Magné
- Radiotherapy and Oncology Department, Institut de Cancérologie Lucien Neuwirth, Saint Priest en Jarez, France
| | | | - Côme Lepage
- Department of Hepato-gastroenterology, University Hospital of Dijon, Dijon, France
| | - Thomas Aparicio
- Gastroenterology and Digestive Oncology Department, Saint Louis Hospital, AP-HP, Paris, France
| |
Collapse
|
2
|
Mamguem Kamga A, Bengrine-Lefevre L, Quipourt V, Favier L, Darut-Jouve A, Marilier S, Arveux P, Desmoulins I, Dabakuyo-Yonli TS. Long-term quality of life and sexual function of elderly people with endometrial or ovarian cancer. Health Qual Life Outcomes 2021; 19:56. [PMID: 33579310 PMCID: PMC7881660 DOI: 10.1186/s12955-021-01675-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2020] [Accepted: 01/12/2021] [Indexed: 11/26/2022] Open
Abstract
Background With the growing number of older endometrial cancer (EC) and ovarian cancer (OC) survivors, data on long-term health-related quality of life (HRQoL) became an important issue in the management of older patients. So, the aim of this study was to describe and compare according to age long-term HRQoL, sexual function, and social deprivation of adults with either EC or OC. Methods A cross-sectional study was set up using data from the Côte d’Or gynecological cancer registry. A series of questionnaires assessing HRQoL (SF-12), sexual function (FSFI), anxiety/depression (HADS), social support (SSQ6) and deprivation (EPICES) were offered to women with EC or OC diagnosed between 2006 and 2013. HRQoL, sexual function, anxiety/depression, social support and deprivation scores were generated and compared according to age (< 70 years and ≥ 70 years). Results A total of 145 women with EC (N = 103) and OC (N = 42) participated in this study. Fifty-six percent and 38% of EC and OC survivors respectively were aged 70 and over. Treatment did not differ according to age either in OC or EC. The deprivation level did not differ between older and younger survivors with OC while older survivors with EC were more precarious. The physical HRQoL was more altered in older EC survivors. This deterioration concerned only physical functioning (MD = 24, p = 0.012) for OC survivors while it concerned physical functioning (MD = 30, p < 0.0001), role physical (MD = 22, p = 0.001) and bodily pain (MD = 21, p = 0.001) for EC survivors. Global health (MD = 11, p = 0.011) and role emotional (MD = 12, p = 0.018) were also deteriorated in elderly EC survivors. Sexual function was deteriorated regardless of age and cancer location with a more pronounced deterioration in elderly EC survivors for desire (p = 0.005), arousal (p = 0.015) and orgasm (p = 0.007). Social support, anxiety and depression were not affected by age regardless of location. Conclusion An average 6 years after diagnosis, the impact of cancer on HRQoL is greatest in elderly survivors with either EC or OC.
Collapse
Affiliation(s)
- Ariane Mamguem Kamga
- Epidemiology and Quality of Life Research Unit, Lipids, Nutrition, Cancer Research Center, INSERM U1231, Georges Francois Leclerc Centre - UNICANCER, 1 rue Professeur Marion, BP 77980, 21079, Dijon Cedex, France
| | - Leila Bengrine-Lefevre
- Medical Oncology Department, Centre Georges-François Leclerc, 1 rue Pr. Marion, 21000, Dijon, France.,Geriatric Oncology Coordination Unit in Burgundy, University Hospital, 21079, Dijon, France
| | - Valérie Quipourt
- Geriatric Oncology Coordination Unit in Burgundy, University Hospital, 21079, Dijon, France.,Department of Geriatrics and Internal Medicine, Hospital of Champmaillot, University Hospital, 21079, Dijon, France
| | - Laure Favier
- Medical Oncology Department, Centre Georges-François Leclerc, 1 rue Pr. Marion, 21000, Dijon, France
| | | | - Sophie Marilier
- Geriatric Oncology Coordination Unit in Burgundy, University Hospital, 21079, Dijon, France.,Department of Geriatrics and Internal Medicine, Hospital of Champmaillot, University Hospital, 21079, Dijon, France
| | - Patrick Arveux
- Epidemiology and Quality of Life Research Unit, Lipids, Nutrition, Cancer Research Center, INSERM U1231, Georges Francois Leclerc Centre - UNICANCER, 1 rue Professeur Marion, BP 77980, 21079, Dijon Cedex, France.,Centre for Research in Epidemiology and Population Health (CESP), INSERM U1018, University Paris-Sud, UVSQ Gustave Roussy, Villejuif, France
| | - Isabelle Desmoulins
- Medical Oncology Department, Centre Georges-François Leclerc, 1 rue Pr. Marion, 21000, Dijon, France
| | - Tienhan Sandrine Dabakuyo-Yonli
- Epidemiology and Quality of Life Research Unit, Lipids, Nutrition, Cancer Research Center, INSERM U1231, Georges Francois Leclerc Centre - UNICANCER, 1 rue Professeur Marion, BP 77980, 21079, Dijon Cedex, France. .,National Quality of Life and Cancer Platform, Dijon, France.
| |
Collapse
|
3
|
Giraud N, Aparicio T, Ronchin P, Bazire LA, Le Malicot K, Lemanski C, Mirabel X, Étienne PL, Lièvre A, Cacheux W, Darut-Jouve A, de la Fouchardière C, Breysacher G, Argo-Leignel D, Tessier A, Magné N, Ben Abdelghani M, Lepage C, Saut O, Vendrely V. Apport de la radiomique sur IRM pour prédire la réponse à 2 ans après chimioradiothérapie des cancers du canal anal localement évolués. Cancer Radiother 2020. [DOI: 10.1016/j.canrad.2020.08.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
4
|
Aparicio T, Ronchin P, Bazire L, Le Malicot K, Lemanski C, Mirabel X, Etienne PL, Lièvre A, Cacheux W, Darut-Jouve A, De La Fouchardiere C, Breysacher G, Argo Leignel D, Tessier A, Magne N, Ben Abdelghani M, Lepage C, Vendrely V. Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase II study with panitumumab (FFCD 0904). J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.3570] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3570 Background: Standard treatment of anal squamous cell carcinoma is 5-fluorouracil (5FU) and mitomycin C (MMC) based chemoradiotherapy (CRT). This phase II study studied the tolerance and complete response (CR) rate at 8 weeks of panitumumab (Pmab) combined with MMC-5FU based CRT. Methods: Patients with locally advanced tumor without metastases (Stage T2, T3 or T4, whatever N stage; Stage N1-N3 whatever T stage) were treated with two RT periods (45Gy in 5 weeks and a boost of 20Gy in 2 weeks) with concomitant CT sessions of 5FU/MMC at RT weeks 1 and 5. Pmab was administered on RT weeks 1, 3, 5 and 7 according to the doses defined by a previous phase 1.study (MMC: 10 mg/m² at J1 and J29; 5FU: 400 mg/m² from J1 to J4 and from J29 to J32, Pmab: 3mg/kg). The expected rate of CR at 8 weeks to continue in phase III was 80%. Results: Forty-five patients (male: 9 (20%), female: 36 (80%); median age: 60.1 [41.5-81]) were enrolled in 15 French centers. All patients but one completed the CRT. Median duration of CRT was 52 days [30-76].Fourteen patients had a RT interruption because of toxicity. Most common related grade 3-4 toxicities observed were digestive (51.1%), hematologic (lymphopenia: 73.4%; neutropenia: 11.1%), radiation dermatitis (28.8%) and asthenia (11.1%). On patient died because of mesenteric ischemia during the CRT (total dose: 36 Gy). In ITT analysis, the CR rate at 8 weeks after CRT was 66.7% [90%CI: 53.4-78.2]. Median follow-up was 16.2 months [14.1-18.2]. Overall survival, recurrence-free and colostomy-free survival at one year were 94.6% [95%CI: 75.8-98.7], 72.2% [95%CI: 55.0-83.7] and 78.2% [95%CI: 60.6 – 88.6] respectively. Six (13%) patients had a colostomy with abdomino-perineal amputation due to a tumour recurrence. Conclusions: Despite an acceptable tolerance, panitumumab in combination with CRT for locally advanced anal cancer failed to meet the expected CR rate to justify further clinical trials. Clinical trial information: NCT01581840.
Collapse
Affiliation(s)
- Thomas Aparicio
- Department of Gastroenterology, Saint Louis Hospital, Paris, France
| | | | - Louis Bazire
- Institut Curie-Radiotherapy Department, Paris, France
| | | | - Claire Lemanski
- Radiation Oncology, Montpellier Val d'Aurelle Cancer Institute, Montpellier, France
| | | | | | | | - Wulfran Cacheux
- Institut Curie-Medical Oncology Department, Saint-Cloud, France
| | | | | | | | | | | | - Nicolas Magne
- Lucien Neuwirth Cancer Institute, Saint-Priest-En-Jarez, France
| | | | - Come Lepage
- Dijon University Hospital, INSERM U1231, Dijon, France
| | | |
Collapse
|
5
|
Curtit E, Henriques J, Paget-Bailly S, Ladoire S, Darut-Jouve A, Debled M, Romieu G, Garnier-Tixidre C, Jacquin JP, Soulie P, Jouannaud C, Rios M, Petit T, Bachelot TD, Faure-Mercier C, Gambotti L, Blanché H, Deleuze JF, Cox D, Pivot X. Prognosis value of a genetic score based on germline genetic variants in a prospective cohort of early triple-negative breast cancer patients. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.1529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1529 Background: Triple-negative breast cancers (TNBC) are a heterogeneous group of tumors with poor outcome. In this study, the association between germline genetic variants and invasive disease-free survival (iDFS) was analyzed in TNBC patients. Methods: A genome wide-association study (GWAS) aimed to identify variants (single nucleotide polymorphisms – SNPs) associated with prognosis in 1121 patients with TNBC in the SIGNAL prospective cohort. Associations between gene variants and iDFS were assessed in univariate Cox regression models. Variants were combined in a score to identify risk categories. A prognostic model based on breast cancer stage and genetic variants was estimated using a multivariate Cox regression. Interaction between stage and genetic score was tested. Discrimination of the model was assessed by the Harrell’s C statistic and internal validity by bootstrap method. Results: The characteristics of the 1121 patients were representative of a population with early TNBC. Four SNPs on chromosomes 9 and 2 were found significantly associated to iDFS in univariate Cox models. Homozygous status for the most frequent allele was associated with poorer iDFS for two SNPs and this status was present in 50% and 57% of the population. For the two other SNPs, the most frequent allele was associated with more favorable iDFS. Three prognostic categories were derived from the genetic score. The following table presents the results from the multivariate Cox model including genetic score and disease stage. Clinical trial information: RECF1098. Conclusions: In a prospective cohort of 1121 patients with early TNBC, 4 genetic variants (SNPs) were associated with iDFS. A score involving SNPs provided similar prognostic indications as breast cancer stages. A search assessing the function and the role of the involved genes is ongoing.[Table: see text]
Collapse
Affiliation(s)
- Elsa Curtit
- University Hospital - Medical Oncology Department, Besançon, France
| | - Julie Henriques
- Methodology and Quality of Life Unit, Department of Oncology University Hospital, Besançon, France
| | - Sophie Paget-Bailly
- Methodological and Quality of Life Unit in Oncology (INSERM UMR 1098), University Hospital, Besançon, France
| | - Sylvain Ladoire
- Dpt of Medical Oncology, Centre Georges François Leclerc, Dijon, France
| | | | | | | | | | - Jean-Philippe Jacquin
- GINECO-Institut de Cancérologie de la Loire Lucien Neuwirth, Saint-Priest-En-Jarez, France
| | | | | | | | - Thierry Petit
- Paul Strauss Cancer Center and University of Strasbourg, Strasbourg, France
| | | | | | | | | | | | | | - Xavier Pivot
- Administrateur de l’Institut Régional du Cancer, Strasbourg Cedex, France
| |
Collapse
|
6
|
Mamguem Kamga A, Dumas A, Joly F, Billa O, Simon J, Poillot ML, Darut-Jouve A, Coutant C, Fumoleau P, Arveux P, Dabakuyo-Yonli TS. Long-Term Gynecological Cancer Survivors in Côte d'Or: Health-Related Quality of Life and Living Conditions. Oncologist 2018; 24:e490-e500. [PMID: 30578310 DOI: 10.1634/theoncologist.2018-0347] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2018] [Accepted: 10/16/2018] [Indexed: 01/20/2023] Open
Abstract
BACKGROUND The likelihood that health-related quality of life (HRQoL) could depend on factors other than clinical data increases with the duration of follow-up since diagnosis. The aim of this study was to identify determinants of long-term HRQoL in women with cervical, endometrial, and ovarian cancer. Secondary objectives were to describe their living conditions (sexual function, psychological distress, social and professional reinsertion). MATERIALS AND METHODS In a cross-sectional survey, women diagnosed with cervical, endometrial, and ovarian cancers from 2006 to 2013 were selected through the French gynecological cancers registry of Côte d'Or. Validated questionnaires exploring HRQoL (short-form health survey; SF-12), anxiety and depression (Hospital Anxiety and Depression Scale), social support (Sarason's Social Support Questionnaire), sexual function (Female Sexual Function Index), and living conditions (EPICES questionnaire) were used to assess HRQoL and its determinants. Social and professional reinsertion were also investigated using study-specific questionnaires. Determinants of HRQoL were identified using a multivariable mixed-regression model for each composite score of the SF-12. RESULTS In total, 195 gynecological cancer survivors participated in the survey. HRQoL was deteriorated for almost all the SF-12 dimensions. The main determinants of poor HRQoL were comorbidities, deprivation, lack of availability and satisfaction with social support, and psychological outcomes. Thirty-four percent of survivors of gynecological cancer reported a negative impact of cancer on their work, and 73% reported an impaired ability to work after treatment. CONCLUSIONS Long-term HRQoL of survivors of gynecological cancer is not impacted by stage of disease. Specific interventions should focus on issues that promote social and professional reintegration and improve HRQoL. IMPLICATIONS FOR PRACTICE This study shows that women with gynecological cancer have problems related to work and sexual dysfunction, even 5 years after diagnosis. The results of this study will help improve clinicians' awareness of the factors affecting the lives of gynecological cancer survivors, even long after diagnosis and treatment. They will also highlight for clinicians the areas that are of importance to gynecological cancer survivors, making it possible to guide management of these patients with a view to preventing deteriorated health-related quality of life after treatment. For the health authorities, the results of this study underline that more than 5 years after gynecological cancer, the initial stage of disease no longer affects quality of life, but there is a clear need for actions targeting socio-professional reintegration of survivors.
Collapse
Affiliation(s)
- Ariane Mamguem Kamga
- Breast and Gynecologic Cancer Registry of Côte d'Or, Georges-François Leclerc Cancer Centre-UNICANCER, Dijon, France
- Lipids, Nutrition, Cancer Research Center, INSERM U1231, Dijon, France
| | - Agnès Dumas
- Centre for Research in Epidemiology and Population Health (CESP), INSERM U1018, Université Paris-Sud, University of Paris-Saclay, Villejuif, France and Department of Clinical Research, Gustave Roussy, INSERM U1018, B2M, Villejuif, France
| | - Florence Joly
- University Hospital Côte de Nacre, François Baclesse Comprehensive Cancer Centre, Medical Oncology Department, INSERM U1086, Caen, France
| | - Oumar Billa
- Breast and Gynecologic Cancer Registry of Côte d'Or, Georges-François Leclerc Cancer Centre-UNICANCER, Dijon, France
- Lipids, Nutrition, Cancer Research Center, INSERM U1231, Dijon, France
| | - Julien Simon
- Breast and Gynecologic Cancer Registry of Côte d'Or, Georges-François Leclerc Cancer Centre-UNICANCER, Dijon, France
| | - Marie-Laure Poillot
- Breast and Gynecologic Cancer Registry of Côte d'Or, Georges-François Leclerc Cancer Centre-UNICANCER, Dijon, France
| | | | - Charles Coutant
- Medical Oncology, Georges-François Leclerc Cancer Centre-UNICANCER, Dijon, France
- Burgundy Franche-Comté University, Dijon, France
| | - Pierre Fumoleau
- Burgundy Franche-Comté University, Dijon, France
- Curie Institute, Paris, France
| | - Patrick Arveux
- Breast and Gynecologic Cancer Registry of Côte d'Or, Georges-François Leclerc Cancer Centre-UNICANCER, Dijon, France
- Lipids, Nutrition, Cancer Research Center, INSERM U1231, Dijon, France
| | - Tienhan Sandrine Dabakuyo-Yonli
- Breast and Gynecologic Cancer Registry of Côte d'Or, Georges-François Leclerc Cancer Centre-UNICANCER, Dijon, France
- Lipids, Nutrition, Cancer Research Center, INSERM U1231, Dijon, France
- National Quality of Life and Cancer Clinical Research Platform, Dijon, France
| |
Collapse
|
7
|
Cox DG, Curtit E, Romieu G, Fumoleau P, Rios M, Bonnefoi H, Bachelot T, Soulié P, Jouannaud C, Bourgeois H, Petit T, Tennevet I, Assouline D, Mathieu MC, Jacquin JP, Lavau-Denes S, Darut-Jouve A, Ferrero JM, Tarpin C, Lévy C, Delecroix V, Trillet-Lenoir V, Cojocarasu O, Meunier J, Pierga JY, Faure-Mercier C, Blanché H, Sahbatou M, Boland A, Bacq D, Besse C, Deleuze JF, Pauporté I, Thomas G, Pivot X. GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients. Oncotarget 2018; 7:77358-77364. [PMID: 27764800 PMCID: PMC5363591 DOI: 10.18632/oncotarget.12669] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2016] [Accepted: 09/14/2016] [Indexed: 01/23/2023] Open
Abstract
Genetic polymorphisms are associated with breast cancer risk. Clinical and epidemiological observations suggest that clinical characteristics of breast cancer, such as estrogen receptor or HER2 status, are also influenced by hereditary factors. To identify genetic variants associated with pathological characteristics of breast cancer patients, a Genome Wide Association Study was performed in a cohort of 9365 women from the French nationwide SIGNAL/PHARE studies (NCT00381901/RECF1098). Strong association between the FGFR2 locus and ER status of breast cancer patients was observed (ER-positive n=6211, ER-negative n=2516; rs3135718 OR=1.34 p=5.46×10-12). This association was limited to patients with HER2-negative tumors (ER-positive n=4267, ER-negative n=1185; rs3135724 OR=1.85 p=1.16×10-11). The FGFR2 locus is known to be associated with breast cancer risk. This study provides sound evidence for an association between variants in the FGFR2 locus and ER status among breast cancer patients, particularly among patients with HER2-negative disease. This refinement of the association between FGFR2 variants and ER-status to HER2-negative disease provides novel insight to potential biological and clinical influence of genetic polymorphisms on breast tumors.
Collapse
Affiliation(s)
- David G Cox
- Centre de Recherche en Cancérologie de Lyon, INSERM U1052 - Centre Léon Bérard, 69373 Lyon, France
| | - Elsa Curtit
- Hôpital Jean-Minjoz, Centre Hospitalier Universitaire, Boulevard Fleming, 25030 Besançon, France
| | - Gilles Romieu
- Oncologie Sénologie, ICM Institut Régional du Cancer, 34298 Montpellier Cedex, France
| | | | - Maria Rios
- Institut de Cancérologie de Lorraine - Alexis Vautrin, Département d'Oncologie Médicale, 54511 Vandœuvre-lès-Nancy Cedex, France
| | - Hervé Bonnefoi
- Institut Bergonié, Département d'Oncologie Médicale, 33000 Bordeaux, France
| | - Thomas Bachelot
- Centre Léon Bérard, Département de Cancérologie Médicale, Lyon Cedex 08, France
| | - Patrick Soulié
- Institut de Cancérologie de l'Ouest, Service Oncologie Médicale, 49993 Angers Cedex 09, France
| | | | - Hugues Bourgeois
- Clinique Victor Hugo-Centre Jean Bernard, 72015 Le Mans Cedex 2, France
| | - Thierry Petit
- Centre Paul Strauss, Service d'Oncologie Médicale, 67065 Strasbourg Cedex, France
| | | | - David Assouline
- Institut Daniel Hollard, Service Oncologie Médicale, 38028 Grenoble Cedex 01, France
| | | | - Jean-Philippe Jacquin
- Institut de Cancérologie Lucien Neuwirth, Service Oncologie Médicale, 42270 Saint Priest en Jarez, France
| | - Sandrine Lavau-Denes
- Centre Hospitalier de Limoges, Service d'Oncologie Médicale, 87042 Limoges Cedex, France
| | - Ariane Darut-Jouve
- Clinique Drévon, Centre d'Oncologie et de Radiothérapie du Parc, 21000 Dijon, France
| | - Jean-Marc Ferrero
- Centre Antoine Lacassagne, Département Oncologie Médicale, 06189 Nice Cedex 02, France
| | - Carole Tarpin
- Institut Paoli-Calmettes, Département d'Oncologie Médicale, 13009 Marseille, France
| | | | - Valérie Delecroix
- Pôle Mutualiste, Service Oncologie Médicale, 44606 Saint Nazaire, France
| | | | - Oana Cojocarasu
- Centre Hospitalier Le Mans, Service d'Onco-Hématologie et Médecine interne, 72037 Le Mans Cedex, France
| | - Jérôme Meunier
- Centre Hospitalier Régional d'Orléans, Service d'Oncologie Médicale, 45032 Orleans Cedex 1, France
| | - Jean-Yves Pierga
- Institut Curie, Department of Medical Oncology, 75248 Paris Cedex 05, France
| | - Céline Faure-Mercier
- Institut National du Cancer, Direction de la Recherche, 92513 Boulogne-Billancourt, France
| | - Hélène Blanché
- Fondation Jean Dausset, Centre d'Etudes du Polymorphisme Humain, 75010 Paris, France
| | - Mourad Sahbatou
- Fondation Jean Dausset, Centre d'Etudes du Polymorphisme Humain, 75010 Paris, France
| | - Anne Boland
- Centre National du Génotypage, Institut de Génomique, CEA, CP 5721, 91057 Evry Cedex, France
| | - Delphine Bacq
- Centre National du Génotypage, Institut de Génomique, CEA, CP 5721, 91057 Evry Cedex, France
| | - Céline Besse
- Centre National du Génotypage, Institut de Génomique, CEA, CP 5721, 91057 Evry Cedex, France
| | - Jean-François Deleuze
- Fondation Jean Dausset, Centre d'Etudes du Polymorphisme Humain, 75010 Paris, France.,Centre National du Génotypage, Institut de Génomique, CEA, CP 5721, 91057 Evry Cedex, France
| | - Iris Pauporté
- Institut National du Cancer, Direction de la Recherche, 92513 Boulogne-Billancourt, France
| | - Gilles Thomas
- Synergie Lyon Cancer, Centre Léon Bérard, Lyon Cedex 08, France
| | - Xavier Pivot
- Hôpital Jean-Minjoz, Centre Hospitalier Universitaire, Boulevard Fleming, 25030 Besançon, France
| |
Collapse
|
8
|
Emile JF, Julié C, Le Malicot K, Lepage C, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Dimet S, Boulagnon-Rombi C, Allard MA, Penault-Llorca F, Bennouna J, Laurent-Puig P, Taieb J, Thaler J, Greil R, Gaenzer J, Eisterer W, Tschmelitsch J, Keil F, Samonigg H, Zabernigg A, Schmid F, Steger G, Steinacher R, Andel J, Jagdt B, Lang A, Fridrik M, Függer R, Hofbauer F, Woell E, Geissler D, Lenauer A, Prager M, D'Haens G, Demolin G, Kerger J, Deboever G, Ghillebert G, Polus M, Van Cutsem E, Kalantari HR, Delaunoit T, Goeminne JC, Peeters M, Vergauwe P, Houbiers G, Humblet Y, Janssens J, Schrijvers D, Vanderstraeten E, Van Laethem JL, Vermorken J, Van Daele D, Ferrante M, Forget F, Hendlisz A, Yilmaz M, Nielsen SE, Vestermark L, Larsen J, Zawadi MA, Bouche O, Mineur L, Bennouna-Louridi J, Dourthe LM, Ychou M, Boucher E, Taieb J, Pezet D, Desseigne F, Ducreux M, Texereau P, Miglianico L, Rougier P, Fratte S, Levache CB, Merrouche Y, Ellis S, Locher C, Ramee JF, Garnier C, Viret F, Chauffert B, Cojean-Zelek I, Michel P, Lecaille C, Borel C, Seitz JF, Smith D, Lombard-Bohas C, Andre T, Gornet JM, Fein F, Coulon-Sfairi MA, Kaminsky MC, Lagasse JP, Luet D, Etienne PL, Gasmi M, Vanoli A, Nguyen S, Aparicio T, Perrier H, Stremsdoerfer N, Laplaige P, Arsene D, Auby D, Bedenne L, Coriat R, Denis B, Geoffroy P, Piot G, Becouarn Y, Bordes G, Deplanque G, Dupuis O, Fruge F, Guimbaud R, Lecomte T, Lledo G, Sobhani I, Asnacios A, Azzedine A, Desauw C, Galais MP, Gargot D, Lam YH, Abakar-Mahamat A, Berdah JF, Catteau S, Clavero-Fabri MC, Codoul JF, Legoux JL, Goldfain D, Guichard P, Verge DP, Provencal J, Vedrenne B, Brezault-Bonnet C, Cleau D, Desir JP, Fallik D, Garcia B, Gaspard MH, Genet D, Hartwig J, Krummel Y, Budnik TM, Palascak-Juif V, Randrianarivelo H, Rinaldi Y, Aleba A, Darut-Jouve A, de Gramont A, Hamon H, Wendehenne F, Matzdorff A, Stahl MK, Schepp W, Burk M, Mueller L, Folprecht G, Geissler M, Mantovani-Loeffler L, Hoehler T, Asperger W, Kroening H, von Weikersthal LF, Fuxius S, Groschek M, Meiler J, Trarbach T, Rauh J, Ziegenhagen N, Kretzschmar A, Graeven U, Nusch A, von Wichert G, Hofheinz RD, Kleber G, Schmidt KH, Vehling-Kaiser U, Baum C, Schuette J, Haag GM, Holtkamp W, Potenberg J, Reiber T, Schliesser G, Schmoll HJ, Schneider-Kappus W, Abenhardt W, Denzlinger C, Henning J, Marxsen B, Derigs HG, Lambertz H, Becker-Boost I, Caca K, Constantin C, Decker T, Eschenburg H, Gabius S, Hebart H, Hoffmeister A, Horst HA, Kremers S, Leithaeuser M, Mueller S, Wagner S, Daum S, Schlegel F, Stauch M, Heinemann V, Maiello E, Latini L, Zaniboni A, Amadori D, Aprile G, Barni S, Mattioli R, Martoni A, Passalacqua R, Nicolini M, Pasquini E, Rabbi C, Aitini E, Ravaioli A, Barone C, Biasco G, Tamberi S, Gambi A, Verusio C, Marzola M, Lelli G, Boni C, Cascinu S, Bidoli P, Vaghi M, Cruciani G, Di Costanzo F, Sobrero A, Mini E, Petrioli R, Aglietta M, Alabiso O, Capuzzo F, Falcone A, Corsi DC, Labianca R, Salvagni S, Chiara S, Ciuffreda L, Ferraù F, Giuliani F, Lonardi S, Gebbia N, Mantovani G, Sanches E, Mellidez JC, Santos P, Freire J, Sarmento C, Costa L, Pinto AM, Barroso S, Santo JE, Guedes F, Monteiro A, Sa A, Furtado I, Salazar R, Aguilar EA, Herrero FR, Tabernero J, Valera JS, Ayerbes MV, Batlle JF, Gil S, Esteve AA, Garcia-Giron C, Vivanco GL, Salvia AS, Orduña VA, Garcia RV, Gallego J, Sureda BM, Remon J, Safont Aguilera MJ, Nogueras LC, Merino BQ, Castro CG, de Prado PM, Pericay CP, Figueiras MC, Jordan IG, Gome Reina MJ, Garcia ALL, Garcia-Ramos AA, Cervantes A, Martos CF, Gaspar EM, Montero IC, Emperador PE, Carbonero AL, Castillo MG, Garcia TG, Lopez JG, Flores EG, Morales MG, Muñoz ML, Martín AL, Maurel J, Camara JC, Garcia RD, Salgado M, Busquier IH, Ruiz TC, Muñoa AL, Aliguer MN, de Taranco AVO, Ureña MM, Gaspa FL, Ponce JJ, Roig CB, Jimenez PV, Brotons AG, Rodriguez SA, Martinez JA, Ruiz LC, Ruiz MC, Bridgewater J, Glynne-Jones R, Tahir S, Hickish T, Cassidy J, Samuel L. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. Eur J Cancer 2017. [DOI: 10.1016/j.ejca.2017.04.025] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
9
|
Curtit E, Pivot X, Henriques J, Paget-Bailly S, Fumoleau P, Rios M, Bonnefoi H, Bachelot T, Soulié P, Jouannaud C, Bourgeois H, Petit T, Tennevet I, Assouline D, Mathieu MC, Jacquin JP, Lavau-Denes S, Darut-Jouve A, Ferrero JM, Tarpin C, Lévy C, Delecroix V, Trillet-Lenoir V, Cojocarasu O, Meunier J, Pierga JY, Kerbrat P, Faure-Mercier C, Blanché H, Sahbatou M, Boland A, Bacq D, Besse C, Thomas G, Deleuze JF, Pauporté I, Romieu G, Cox DG. Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes. Breast Cancer Res 2017; 19:98. [PMID: 28830573 PMCID: PMC5568360 DOI: 10.1186/s13058-017-0888-4] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2016] [Accepted: 08/04/2017] [Indexed: 12/17/2022] Open
Abstract
Background Genome-wide association studies (GWAS) have to date identified 94 genetic variants (single nucleotide polymorphisms (SNPs)) associated with risk of developing breast cancer. A score based on the combined effect of the 94 risk alleles can be calculated to measure the global risk of breast cancer. We aimed to test the hypothesis that the 94-SNP-based risk score is associated with clinico-pathological characteristics, breast cancer subtypes and outcomes in early breast cancer. Methods A 94-SNP risk score was calculated in 8703 patients in the PHARE and SIGNAL prospective case cohorts. This score is the total number of inherited risk alleles based on 94 selected SNPs. Clinical data and outcomes were prospectively registered. Genotyping was obtained from a GWAS. Results The median 94-SNP risk score in 8703 patients with early breast cancer was 77.5 (range: 58.1–97.6). The risk score was not associated with usual prognostic and predictive factors (age; tumor, node, metastasis (TNM) status; Scarff-Bloom-Richardson grade; inflammatory features; estrogen receptor status; progesterone receptor status; human epidermal growth factor receptor 2 (HER2) status) and did not correlate with breast cancer subtypes. The 94-SNP risk score did not predict outcomes represented by overall survival or disease-free survival. Conclusions In a prospective case cohort of 8703 patients, a risk score based on 94 SNPs was not associated with breast cancer characteristics, cancer subtypes, or patients’ outcomes. If we hypothesize that prognosis and subtypes of breast cancer are determined by constitutional genetic factors, our results suggest that a score based on breast cancer risk-associated SNPs is not associated with prognosis. Trial registration PHARE cohort: NCT00381901, Sept. 26, 2006 – SIGNAL cohort: INCa RECF1098, Jan. 28, 2009 Electronic supplementary material The online version of this article (doi:10.1186/s13058-017-0888-4) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Elsa Curtit
- Hôpital Jean-Minjoz, Centre Hospitalier Universitaire, UMR 1098 INSERM-EFS-Université de Bourgogne Franche-Comté, Boulevard Fleming, 25000, Besançon, France. .,Department of Medical Oncology, University Hospital Jean Minjoz, 3, boulevard Alexandre Fleming, 25030, Besancon Cedex, France.
| | - Xavier Pivot
- Hôpital Jean-Minjoz, Centre Hospitalier Universitaire, UMR 1098 INSERM-EFS-Université de Bourgogne Franche-Comté, Boulevard Fleming, 25000, Besançon, France
| | - Julie Henriques
- Centre Hospitalier Universitaire, Unité de Méthodologie et de Qualité de Vie en Cancérologie, 2 place St Jacques, 25000, Besançon, France
| | - Sophie Paget-Bailly
- Centre Hospitalier Universitaire, Unité de Méthodologie et de Qualité de Vie en Cancérologie, 2 place St Jacques, 25000, Besançon, France
| | - Pierre Fumoleau
- Georges-François Leclerc, 1 Rue du Professeur Marion, 21000, Dijon, France
| | - Maria Rios
- Institut de Cancérologie de Lorraine - Alexis Vautrin, département d'Oncologie Médicale, 6, avenue de Bourgogne, 54511, Vandoeuvre Les Nancy Cedex, France
| | - Hervé Bonnefoi
- Institut Bergonié, Département d'Oncologie Médicale, 229 Cours de l'Argonne, 33000, Bordeaux, France
| | - Thomas Bachelot
- Centre Léon Bérard, Département de Cancérologie Médicale, 28 rue Laënnec, Lyon Cedex 08, France
| | - Patrick Soulié
- Institut de Cancérologie de l'Ouest, Service Oncologie Médicale, 2 rue Moll, 49993, Angers Cedex 09, France
| | - Christelle Jouannaud
- Institut Jean Godinot, Service Oncologie Médicale, 1 rue du Général Koenig, 51056, Reims cedex, France
| | - Hugues Bourgeois
- Clinique Victor Hugo-Centre Jean Bernard, 18 rue Victor Hugo, 72015, Le Mans Cedex 2, France
| | - Thierry Petit
- Centre Paul Strauss, Service d'Oncologie Médicale, 3 rue de la Porte de l'Hôpital, 67065, Strasbourg Cedex, France
| | | | - David Assouline
- Institut Daniel Hollard, Service Oncologie Médicale, 8 rue du Docteur Calmette, 38028, Grenoble Cedex 01, France
| | - Marie-Christine Mathieu
- Institut Gustave Roussy, Comité de Pathologie mammaire, 39 rue Camille Desmoulins, 94805, Villejuif Cedex, France
| | - Jean-Philippe Jacquin
- Institut de Cancérologie Lucien Neuwirth, Service Oncologie Médicale, 108 bis avenue Albert Raimond, 42270, Saint Priest en Jarez, France
| | - Sandrine Lavau-Denes
- Centre Hospitalier de Limoges, Service d'Oncologie Médicale, 2 avenue Martin Luther King, 87042, Limoges Cedex, France
| | - Ariane Darut-Jouve
- Clinique Drévon, Centre d'oncologie et de radiothérapie du Parc, 18 cours du général de Gaulle, 21000, Dijon, France
| | - Jean-Marc Ferrero
- Centre Antoine Lacassagne, Département Oncologie Médicale, 33 avenue de Valombrose, 06189, Nice Cedex 02, France
| | - Carole Tarpin
- Institut Paoli-Calmettes, Département d'Oncologie Médicale, 232 Boulevard de Sainte-Marguerite, 13009, Marseille, France
| | - Christelle Lévy
- Centre François Baclesse, 3 avenue du Général Harris, 14076, Caen Cedex 5, France
| | - Valérie Delecroix
- Centre Etienne Dolet, Pôle Mutualiste, Service Oncologie Médicale, 11 boulevard Georges Charpak, 44606, Saint Nazaire, France
| | - Véronique Trillet-Lenoir
- Centre Hospitalier Lyon Sud, Service d'Oncologie Médicale, 165 chemin du Grand Revoyet, 69495, Pierre-Benite Cedex, France
| | - Oana Cojocarasu
- Centre Hospitalier Le Mans, Service d'Onco-Hématologie et Médecine interne, 194 avenue Rubillard, 72037, Le Mans Cedex, France
| | - Jérôme Meunier
- Centre Hospitalier Régional d'Orléans, Service d'Oncologie médicale, 1 rue Porte Madeleine, 45032, Orleans Cedex 1, France
| | - Jean-Yves Pierga
- Institut Curie, Department of Medical Oncology, 26 rue d'Ulm, 75248, Paris Cedex 05, France
| | - Pierre Kerbrat
- Centre Eugène Marquis, Service Oncologie médicale, Rue de la Bataille Flandres-Dunkerque, CS 44229, 35042, Rennes Cedex, France
| | - Céline Faure-Mercier
- Institut National du Cancer, Direction de la Recherche, 52 avenue Morizet, 92513, Boulogne-Billancourt, France
| | - Hélène Blanché
- Centre d'Etudes du Polymorphisme Humain, 27 rue Juliette Dodu, 75010, Paris, France
| | - Mourad Sahbatou
- Centre d'Etudes du Polymorphisme Humain, 27 rue Juliette Dodu, 75010, Paris, France
| | - Anne Boland
- Centre National du Génotypage, 2 rue Gaston Crémieux, CP 5721, 91057, Evry Cedex, France
| | - Delphine Bacq
- Centre National du Génotypage, 2 rue Gaston Crémieux, CP 5721, 91057, Evry Cedex, France
| | - Céline Besse
- Centre National du Génotypage, 2 rue Gaston Crémieux, CP 5721, 91057, Evry Cedex, France
| | - Gilles Thomas
- Synergie Lyon Cancer, Centre Léon Bérard, 28 rue Laënnec, Lyon Cedex 08, France
| | - Jean-François Deleuze
- Centre d'Etudes du Polymorphisme Humain, 27 rue Juliette Dodu, 75010, Paris, France.,Centre National du Génotypage, 2 rue Gaston Crémieux, CP 5721, 91057, Evry Cedex, France
| | - Iris Pauporté
- Institut National du Cancer, Direction de la Recherche, 52 avenue Morizet, 92513, Boulogne-Billancourt, France
| | - Gilles Romieu
- Oncologie Sénologie, ICM Institut Régional du Cancer, 34298, Montpellier Cedex, France
| | - David G Cox
- Centre de Recherche en Cancérologie de Lyon, INSERM U1052 - Centre Léon Bérard, 28 rue Laennec, 69373, Lyon, France
| |
Collapse
|
10
|
Pivot X, Romieu G, Fumoleau P, Rios M, Bonnefoi H, Bachelot T, Soulié P, Jouannaud C, Bourgeois H, Petit T, Tennevet I, Assouline D, Mathieu MC, Jacquin JP, Lavau-Denes S, Darut-Jouve A, Ferrero JM, Tarpin C, Lévy C, Delecroix V, Trillet-Lenoir V, Cojocarasu O, Meunier J, Pierga JY, Agostini C, Kerbrat P, Faure-Mercier C, Blanché H, Sahbatou M, Boland A, Bacq D, Besse C, Calvo F, Renaud A, Deleuze JF, Pauporté I, Thomas G, Cox DG. Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort. NPJ Breast Cancer 2017. [PMID: 28649644 PMCID: PMC5445615 DOI: 10.1038/s41523-017-0005-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
Human epidermal growth factor receptor 2-positive breast cancer is a subtype of interest regarding its outcome and the impressive impact of human epidermal growth factor receptor 2 targeted therapy. Constitutional variants may be involved in the aetiology of human epidermal growth factor receptor 2-positive breast cancer, and we propose a case–case study to test the hypothesis that single nucleotide polymorphisms may be associated with human epidermal growth factor receptor 2 status. A Genome-Wide Association Study was used in a cohort of 9836 patients from the SIGNAL/PHARE study (NCT00381901-RECF1098). The main goal was to identify variants specifically related to human epidermal growth factor receptor 2-positive breast cancer. A two-staged genotyping strategy was carried out to cover as large a proportion of the genome as possible. All subjects were genotyped using the Illumina HumanCore Exome chip set. Principal Components Analysis and k-means were then used to characterize the ancestry of the participants. A random sample of subjects from the main “European” cluster was genotyped with the Omni5 chip set. These data were then used to impute missing genotypes from the remaining subjects genotyped only using the HumanCore Exome array. From the 9836 patients, a total of 8703 cases including 3230 patients with human epidermal growth factor receptor 2-positive breast cancer were analyzed. Despite having 80% power to detect an odds ratio of 1.23 in this population, no variant achieved genome-wide significance for association with the occurrence of human epidermal growth factor receptor 2–positive breast cancer vs. any other subtype of breast tumour. Our study was unable to identify constitutional polymorphisms that are strongly associated with human epidermal growth factor receptor 2-positive status among breast cancer patients. A large gene-finding study failed to identify any hereditary factors linked to HER2 expression among women with breast cancer. A team in France led by Xavier Pivot from the University Hospital Center of Besançon, France, analyzed more than 500,000 single DNA letters from a cohort of 8703 patients with breast cancer, 3230 of whom had tumors with high expression of human epidermal growth factor receptor 2 (HER2) and are thus treated with for anti-HER2 targeted therapies. The researchers searched for DNA variants associated with HER2 status, but none reached the threshold for statistical significance. The findings reveal a high level of genetic diversity in women with HER2-positive breast cancer and suggest that HER2 amplification may have more to do with the intrinsic nature of the tumor than with the genetics of the patient.
Collapse
Affiliation(s)
- Xavier Pivot
- Hôpital Jean-Minjoz, Centre Hospitalier Universitaire INSERM 1098, Boulevard Fleming, Besançon, 25030 France
| | - Gilles Romieu
- Oncologie Sénologie, ICM Institut Régional du Cancer, Montpellier, CEDEX 34298 France
| | - Pierre Fumoleau
- Georges-François Leclerc, 1 Rue du Professeur Marion, Dijon, 21000 France
| | - Maria Rios
- Département d'Oncologie Médicale, Institut de Cancérologie de Lorraine-Alexis Vautrin, 6, avenue de Bourgogne, VANDOEUVRE LES NANCY, CEDEX 54511 France
| | - Hervé Bonnefoi
- Département d'Oncologie Médicale, Institut Bergonié, 229 Cours de l'Argonne, Bordeaux, 33000 France
| | - Thomas Bachelot
- Département de Cancérologie Médicale, Centre Léon Bérard, 28 rue Laënnec, Lyon, CEDEX 08 France
| | - Patrick Soulié
- Institut de Cancérologie de l'Ouest, Service Oncologie Médicale, 2 rue Moll, Angers, CEDEX 09 49993 France
| | - Christelle Jouannaud
- Institut Jean Godinot, Service Oncologie Médicale, 1 rue du Général Koenig, Reims, CEDEX 51056 France
| | - Hugues Bourgeois
- Clinique Victor Hugo-Centre Jean Bernard, 18 rue Victor Hugo, Le Mans, CEDEX 2 72015 France
| | - Thierry Petit
- Centre Paul Strauss, Service d'Oncologie Médicale, 3 rue de la Porte de l'Hôpital, Strasbourg, CEDEX 67065 France
| | | | - David Assouline
- Institut Daniel Hollard, Service Oncologie Médicale, 8 rue du Docteur Calmette, Grenoble, CEDEX 01 38028 France
| | - Marie-Christine Mathieu
- Institut Gustave Roussy, Comité de Pathologie mammaire, 39 rue Camille Desmoulins, Villejuif, CEDEX 94805 France
| | - Jean-Philippe Jacquin
- Institut de Cancérologie Lucien Neuwirth, Service Oncologie Médicale, 108 bis avenue Albert Raimond, Saint Priest en Jarez, 42270 France
| | - Sandrine Lavau-Denes
- Centre Hospitalier de Limoges, Service d'Oncologie Médicale, 2 avenue Martin Luther King, Limoges, CEDEX 87042 France
| | - Ariane Darut-Jouve
- Clinique Drévon, Centre d'oncologie et de radiothérapie du Parc, 18 cours du général de Gaulle, Dijon, 21000 France
| | - Jean-Marc Ferrero
- Département Oncologie Médicale, Centre Antoine Lacassagne, 33 avenue de Valombrose, Nice, CEDEX 02 06189 France
| | - Carole Tarpin
- Département d'Oncologie Médicale, Institut Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, Marseille, 13009 France
| | - Christelle Lévy
- Centre François Baclesse, 3 avenue du Général Harris, Caen, CEDEX 5 14076 France
| | - Valérie Delecroix
- Centre Etienne Dolet, Pôle Mutualiste, Service Oncologie Médicale, 11 boulevard Georges Charpak, Saint Nazaire, 44606 France
| | - Véronique Trillet-Lenoir
- Centre Hospitalier Lyon Sud, Service d'Oncologie Médicale, 165 chemin du Grand Revoyet, Pierre-Benite cedex, 69495 France
| | - Oana Cojocarasu
- Centre Hospitalier Le Mans, Service d'Onco-Hématologie et Médecine interne, 194 avenue Rubillard, Le Mans, CEDEX 72037 France
| | - Jérôme Meunier
- Centre Hospitalier Régional d'Orléans, Service d'Oncologie médicale, 1 rue Porte Madeleine, ORLEANS, CEDEX 1 45032 France
| | - Jean-Yves Pierga
- Department of Medical Oncology, Institut Curie, 26 rue d'Ulm, Paris, CEDEX 05 75248 France
| | - Cécile Agostini
- Centre Hospitalier de Chambéry, Service Oncologie médicale, Place du Docteur François Chiron, Chambéry, 73000 France
| | - Pierre Kerbrat
- Centre Eugène Marquis, Service Oncologie médicale, Rue de la Bataille Flandres-Dunkerque, CS 44229, Rennes, CEDEX 35042 France
| | - Céline Faure-Mercier
- Institut National du Cancer, Direction de la Recherche, 52 avenue Morizet, Boulogne-Billancourt, 92513 France
| | - Hélène Blanché
- Centre d'Etudes du Polymorphisme Humain, 27 rue Juliette Dodu, Paris, 75010 France
| | - Mourad Sahbatou
- Centre d'Etudes du Polymorphisme Humain, 27 rue Juliette Dodu, Paris, 75010 France
| | - Anne Boland
- Centre National du Génotypage, 2 rue Gaston Crémieux, CP 5721, Evry, CEDEX 91057 France
| | - Delphine Bacq
- Centre National du Génotypage, 2 rue Gaston Crémieux, CP 5721, Evry, CEDEX 91057 France
| | - Céline Besse
- Centre National du Génotypage, 2 rue Gaston Crémieux, CP 5721, Evry, CEDEX 91057 France
| | - Fabien Calvo
- Institut Gustave Roussy, Comité de Pathologie mammaire, 39 rue Camille Desmoulins, Villejuif, CEDEX 94805 France
| | - Alexia Renaud
- Centre de Recherche en Cancérologie de Lyon, INSERM U1052-Centre Léon Bérard, 28 rue Laennec, Lyon, 69373 France
| | - Jean-François Deleuze
- Centre d'Etudes du Polymorphisme Humain, 27 rue Juliette Dodu, Paris, 75010 France.,Centre National du Génotypage, 2 rue Gaston Crémieux, CP 5721, Evry, CEDEX 91057 France
| | - Iris Pauporté
- Institut National du Cancer, Direction de la Recherche, 52 avenue Morizet, Boulogne-Billancourt, 92513 France
| | - Gilles Thomas
- Synergie Lyon Cancer, Centre Léon Bérard, 28 rue Laënnec, Lyon, CEDEX 08 France
| | - David G Cox
- Centre de Recherche en Cancérologie de Lyon, INSERM U1052-Centre Léon Bérard, 28 rue Laennec, Lyon, 69373 France
| |
Collapse
|
11
|
Auguste A, Cortet M, Dabakuyo-Yonli TS, Launay L, Arnould L, Desmoulins I, Roignot P, Darut-Jouve A, Poillot ML, Bertaut A, Arveux P. Breast cancer subtype of French women is not influenced by socioeconomic status: A population-based-study. PLoS One 2017; 12:e0170069. [PMID: 28199325 PMCID: PMC5310911 DOI: 10.1371/journal.pone.0170069] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2016] [Accepted: 12/28/2016] [Indexed: 01/08/2023] Open
Abstract
Context The molecular subtype of breast tumours plays a major role in cancer prognosis and treatment options. Triple negative tumours (TN) carry the worst prognosis and affects most frequently women of low socioeconomic status (SES). Studies have shown that non-biologic factors, such as the socioeconomic status could have an influence on tumour biology. To this date no study has been done investigating this association in French women. The objective is to study the association between the SES and the molecular tumour subtype of breast cancer patients in the French county of Côte d’Or. This study benefits from the population data from the Côte d’Or breast cancer registry known for its strict quality control policy. Methods Invasive breast cancer cases between 2003 and 2013 were extracted from the Breast cancer registry database in Côte d’Or. A multivariate analysis was conducted using a hierarchical polytomous regression for the multinomial outcomes for the cancer subtype with HR+/HER2 as reference category. Results A total of 4553 cases were included in our study. There was no significant association found between SES and tumour subtype in French women at diagnosis. Women older than 75 years were less likely to have a TN and HR+/HER2+ breast cancer (OR = 0.66; CI95% = [0.46–0.94] and OR = 0.51; CI95% = [0.37–0.70] respectively). Women with TN tumour subtype had significantly less lymph node invasion when compared to HR+/HER2- subtype (OR = 0.71; CI95% = [0.54–0.92]). Conclusion No significant association was found between socioeconomic status and molecular subtype. Further studies are needed to clarify the mechanisms associated with developing each tumour subtype.
Collapse
Affiliation(s)
- Aviane Auguste
- Breast and Gynaecologic Cancer Registry of Côte d’Or, Georges-François Leclerc Comprehensive Cancer Care Centre, 1 rue du Professeur Marion, Dijon, France
- EA 4184, Medical School, University of Burgundy, 7 boulevard Jeanne d’Arc, Dijon, France
| | - Marion Cortet
- Breast and Gynaecologic Cancer Registry of Côte d’Or, Georges-François Leclerc Comprehensive Cancer Care Centre, 1 rue du Professeur Marion, Dijon, France
| | - Tienhan Sandrine Dabakuyo-Yonli
- Breast and Gynaecologic Cancer Registry of Côte d’Or, Georges-François Leclerc Comprehensive Cancer Care Centre, 1 rue du Professeur Marion, Dijon, France
- EA 4184, Medical School, University of Burgundy, 7 boulevard Jeanne d’Arc, Dijon, France
| | - Ludivine Launay
- Plateforme ERISC, U 1086 INSERM "Cancers and Preventions", François Baclesse Comprehensive Cancer Care Centre, 3 avenue du Général Harris, CAEN, France
| | - Laurent Arnould
- Breast and Gynaecologic Cancer Registry of Côte d’Or, Georges-François Leclerc Comprehensive Cancer Care Centre, 1 rue du Professeur Marion, Dijon, France
| | - Isabelle Desmoulins
- Breast and Gynaecologic Cancer Registry of Côte d’Or, Georges-François Leclerc Comprehensive Cancer Care Centre, 1 rue du Professeur Marion, Dijon, France
| | | | | | - Marie-Laure Poillot
- Breast and Gynaecologic Cancer Registry of Côte d’Or, Georges-François Leclerc Comprehensive Cancer Care Centre, 1 rue du Professeur Marion, Dijon, France
| | - Aurélie Bertaut
- EA 4184, Medical School, University of Burgundy, 7 boulevard Jeanne d’Arc, Dijon, France
- Biostatistics Unit, Georges-François Leclerc Comprehensive Cancer Care Centre, 1 rue du Professeur Marion, Dijon, France
| | - Patrick Arveux
- Breast and Gynaecologic Cancer Registry of Côte d’Or, Georges-François Leclerc Comprehensive Cancer Care Centre, 1 rue du Professeur Marion, Dijon, France
- EA 4184, Medical School, University of Burgundy, 7 boulevard Jeanne d’Arc, Dijon, France
- * E-mail:
| |
Collapse
|
12
|
Marshall EM, Bertaut A, Desmoulins I, Darut-Jouve A, Ponnelle T, Poillot ML, Beltjens F, Arveux P. Prognostic Factors of Survival among Women with Metastatic Breast Cancer and Impact of Primary or Secondary Nature of Disease on Survival: A French Population-Based Study. Breast J 2016; 23:138-145. [DOI: 10.1111/tbj.12717] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- Esaie M. Marshall
- Côte d'Or Breast Cancer Registry; CGFL; Dijon France
- Research Unit 4184; Faculty of Medicine; University of Burgundy; Dijon France
| | - Aurélie Bertaut
- Methodology and Biostatistic Unit; Centre Georges François Leclerc; Dijon France
| | | | | | | | | | | | - Patrick Arveux
- Côte d'Or Breast Cancer Registry; CGFL; Dijon France
- Research Unit 4184; Faculty of Medicine; University of Burgundy; Dijon France
| |
Collapse
|
13
|
Lepage C, Phelip JM, Cany L, Maillard E, Lievre A, Chatellier T, Faroux R, Duchmann JC, Ben Abdelghani M, Breysacher G, Geoffroy P, Pere-Verge D, Pelaquier A, Pillon D, Ezenfis J, Rinaldi Y, Darut-Jouve A, Duluc M, Adenis A, Bouché O. Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer - PRODIGE 13 a FFCD and Unicancer phase III trial: baseline characteristics. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw370.31] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
Curtit E, Vincent-Salomon A, Paget-Bailly S, Romieu G, Fumoleau P, Bonnefoi H, Jouannaud C, Petit T, Darut-Jouve A, Trillet-Lenoir V, Tarpin C, Pierga JY, Rios M, Jacquin J, Bachelot T, Cox D, Deleuze JF, Pauporte I, Henriques J, Pivot X. Effects of HER2 immuno-histochemistry expression levels on survival in patients treated by trastuzumab at the adjuvant setting in the SIGNAL/PHARE prospective cohort. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw364.40] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
15
|
Thaler J, Greil R, Gaenzer J, Eisterer W, Tschmelitsch J, Samonigg H, Zabernigg A, Schmid F, Steger G, Steinacher R, Andel J, Lang A, Függer R, Hofbauer F, Woell E, Geissler D, Lenauer A, Prager M, Van Laethem JL, Van Cutsem E, D'Haens G, Demolin G, Kerger J, Deboever G, Ghillebert G, Polus M, Van Cutsem E, RezaieKalantari H, Delaunoit T, Goeminne JC, Peeters M, Vergauwe P, Houbiers G, Humblet Y, Janssens J, Schrijvers D, Vanderstraeten E, Van Laethem JL, Vermorken J, Van Daele D, Ferrante M, Forget F, Hendlisz A, Yilmaz M, Nielsen SE, Vestermark L, Larsen J, Ychou M, Zawadi A, Zawadi MA, Bouche O, Mineur L, Bennouna-Louridi J, Dourthe LM, Ychou M, Boucher E, Taieb J, Pezet D, Desseigne F, Ducreux M, Texereau P, Miglianico L, Rougier P, Fratte S, Levache CB, Merrouche, Y, Ellis S, Locher C, Ramee JF, Garnier C, Viret F, Chauffert B, Cojean-Zelek I, Michel P, Lecaille C, Borel C, Seitz JF, Smith D, Lombard-Bohas C, Andre T, Gornet JM, Fein F, Coulon-Sfairi MA, Kaminsky MC, Lagasse JP, Luet D, Etienne PL, Gasmi M, Vanoli A, Nguyen S, Aparicio T, Perrier H, Stremsdoerfer N, Laplaige P, Arsene D, Auby D, Bedenne L, Coriat R, Denis B, Geoffroy P, Piot G, Becouarn Y, Bordes G, Deplanque G, Dupuis O, Fruge F, Guimbaud R, Lecomte T, Lledo G, Sobhani I, Asnacios A, Azzedine A, Desauw C, Galais MP, Gargot D, Lam YH, Abakar-Mahamat A, Berdah JF, Catteau S, Clavero-Fabri MC, Codoul JF, Legoux JL, Goldfain D, Guichard P, Verge DP, Provencal J, Vedrenne B, Brezault-Bonnet C, Cleau D, Desir JP, Fallik D, Garcia B, Gaspard MH, Genet D, Hartwig J, Krummel Y, MatysiakBudnik T, Palascak-Juif V, Randrianarivelo H, Rinaldi Y, Aleba A, Darut-Jouve A, de Gramont A, Hamon H, Wendehenne F, Matzdorff A, Stahl MK, Schepp W, Burk M, Mueller L, Folprecht G, Geissler M, Mantovani-Loeffler L, Hoehler T, Asperger W, Kroening H, von Weikersthal LF, Fuxius S, Groschek M, Meiler J, Trarbach T, Rauh J, Ziegenhagen N, Kretzschmar A, Graeven U, Nusch A, von Wichert G, Hofheinz RD, Kleber G, Schmidt KH, Vehling-Kaiser U, Baum C, Schuette J, Haag GM, Holtkamp W, Potenberg J, Reiber T, Schliesser G, Schmoll HJ, Schneider-Kappus W, Abenhardt W, Denzlinger C, Henning J, Marxsen B, GuenterDerigs H, Lambertz H, Becker-Boost I, Caca K, Constantin C, Decker T, Eschenburg H, Gabius S, Hebart H, Hoffmeister A, Horst HA, Kremers S, Leithaeuser M, Mueller S, Wagner S, Daum S, Schlegel F, Stauch M, Heinemann V, Labianca R, Colucci G, Amadori D, Mini E, Falcone A, Boni C, Maiello E, Latini L, Zaniboni A, Amadori D, Aprile G, Barni S, Mattioli R, Martoni A, Passalacqua R, Nicolini M, Pasquini E, Rabbi C, Aitini E, Ravaioli A, Barone C, Biasco G, Tamberi S, Gambi A, Verusio C, Marzola M, Lelli G, Boni C, Cascinu S, Bidoli P, Vaghi M, Cruciani G, Di Costanzo F, Sobrero A, Mini E, Petrioli R, Aglietta M, Alabiso O, Capuzzo F, Falcone A, Corsi DC, Labianca R, Salvagni S, Chiara S, Ferraù F, Giuliani F, Lonardi S, Gebbia N, Mantovani G, Sanches E, Sanches E, Mellidez JC, Santos P, Freire J, Sarmento C, Costa L, Pinto AM, Barroso S, Santo JE, Guedes F, Monteiro A, Sa A, Furtado I, Tabernero J, Salazar R, Aguilar EA, Herrero FR, Tabernero J, Valera JS, ValladaresAyerbes M, FeliuBatlle J, Gil S, Garcia-Giron C, Vivanco GL, Salvia AS, Orduña VA, Garcia RV, Gallego J, Sureda BM, Remon J, Safont Aguilera MJ, CireraNogueras L, Merino B, Castro CG, de Prado PM, PijaumePericay C, ConstenlaFigueiras M, Jordan I, GomeReina MJ, Garcia ALL, Garcia-Ramos AA, Cervantes A, Martos CF, MarcuelloGaspar E, Montero IC, Emperador PE, Carbonero AL, Castillo MG, Garcia TG, Lopez JG, Flores EG, GuillotMorales M, LlanosMuñoz M, Martín AL, Maurel J, Camara JC, Garcia RD, Salgado M, HernandezBusquier I, Ruiz TC, LacastaMuñoa A, Aliguer M, Ortiz de Taranco AV, Ureña MM, Gaspa FL, Ponce JJ, Roig CB, Jimenez PV, GalanBrotons A, AlbiolRodriguez S, Martinez JA, Ruiz LC, CentellesRuiz M, Bridgewater J, Glynne-Jones R, Tahir S, Hickish T, Cassidy J, Samuel L. Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. Ann Oncol 2015; 26:822-825. [DOI: 10.1093/annonc/mdv070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
Bertaut A, Mounier M, Desmoulins I, Guiu S, Beltjens F, Darut-Jouve A, Ponnelle T, Arnould L, Arveux P. Stage IV breast cancer: a population-based study about prognostic factors according to HER2 and HR status. Eur J Cancer Care (Engl) 2015; 24:920-8. [PMID: 25757548 DOI: 10.1111/ecc.12306] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/08/2015] [Indexed: 11/29/2022]
Abstract
We aim to describe trends in net survival (NS) and to assess the prognostic factors among women with de novo metastatic breast cancer (MBC) according to human epidermal growth factor receptor 2 (HER2) and hormone receptor (HR) status. Data on women suffering from de novo MBC and diagnosed from 1998 to 2009 were provided by the Côte-d'Or breast cancer registry. NS was described using the Pohar Perme estimator and prognostic factors were investigated in a generalised linear model. We identified 232 patients (mean age = 64.7). Median NS was 29.2 months, 1- and 5-year NS were 76% and 26% respectively. The survival trend in patients with HER2-positive tumours who did not receive trastuzumab was similar to that in women with triple-negative tumours. A higher relative excess risk of death by cancer was observed for high-grade tumours [RER, relative excess rates = 1.76 (95% CI, confidence intervals: 1.17-2.62) for Scarff Bloom Richardson grade 3 vs. 1 + 2], while a lower risk was observed for luminal tumours [RER = 0.49 (95% CI: 0.27-0.89)] and HER2-positive tumours treated with trastuzumab [RER = 0.28 (95% CI: 0.14-0.59)], both compared with triple-negative tumours. Surgery of the primary tumour was associated with better survival [RER = 0.43 (95% CI: 0.28-0.68)]. With half of the women dead before 29 months, stage IV breast cancer still has a bleak outlook. Progress should continue with new target therapies for both HR and HER2 receptors.
Collapse
Affiliation(s)
- A Bertaut
- Côte d'Or Breast Cancer Registry, CGFL, Dijon, France.,EA 4184 Centre d'Epidémiologie des populations, University of Burgundy, Dijon, France
| | - M Mounier
- Faculty of Medicine, Hemopathies Registry, Dijon, France
| | - I Desmoulins
- Department of Medical Oncology, CGFL, Dijon, France
| | - S Guiu
- Department of Medical Oncology, CGFL, Dijon, France
| | - F Beltjens
- Department of Pathology, CGFL, Dijon, France
| | | | | | - L Arnould
- Department of Pathology, CGFL, Dijon, France
| | - P Arveux
- Côte d'Or Breast Cancer Registry, CGFL, Dijon, France.,EA 4184 Centre d'Epidémiologie des populations, University of Burgundy, Dijon, France
| |
Collapse
|
17
|
Dialla PO, Quipourt V, Gentil J, Marilier S, Poillot ML, Roignot P, Altwegg T, Darut-Jouve A, Guiu S, Arveux P, Dabakuyo-Yonli TS. In breast cancer, are treatments and survival the same whatever a patient's age? A population-based study over the period 1998-2009. Geriatr Gerontol Int 2014; 15:617-26. [DOI: 10.1111/ggi.12327] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/27/2014] [Indexed: 11/30/2022]
Affiliation(s)
- Pegdwende Olivia Dialla
- Breast and Gynaecologic Cancer Registry of Côte d'Or; Centre Georges François Leclerc Comprehensive Cancer Centre; Dijon Cedex France
- EA 4184; Faculty of Medicine; University of Burgundy; Dijon France
| | - Valérie Quipourt
- Coordination Unit in Geriatric Oncology in Burgundy; Hôpital de jour Gériatrique; Hôpital de Champmaillot; Dijon Cedex France
| | - Julie Gentil
- Breast and Gynaecologic Cancer Registry of Côte d'Or; Centre Georges François Leclerc Comprehensive Cancer Centre; Dijon Cedex France
- EA 4184; Faculty of Medicine; University of Burgundy; Dijon France
| | - Sophie Marilier
- Coordination Unit in Geriatric Oncology in Burgundy; Hôpital de jour Gériatrique; Hôpital de Champmaillot; Dijon Cedex France
| | - Marie-Laure Poillot
- Breast and Gynaecologic Cancer Registry of Côte d'Or; Centre Georges François Leclerc Comprehensive Cancer Centre; Dijon Cedex France
- EA 4184; Faculty of Medicine; University of Burgundy; Dijon France
| | | | | | | | - Sévérine Guiu
- Department of Medical Oncology; Centre Georges François Leclerc Comprehensive Cancer Centre; Dijon Cedex France
| | - Patrick Arveux
- Breast and Gynaecologic Cancer Registry of Côte d'Or; Centre Georges François Leclerc Comprehensive Cancer Centre; Dijon Cedex France
- EA 4184; Faculty of Medicine; University of Burgundy; Dijon France
| | - Tienhan Sandrine Dabakuyo-Yonli
- EA 4184; Faculty of Medicine; University of Burgundy; Dijon France
- Biostatistics and Quality of Life Unit; Centre Georges François Leclerc Comprehensive Cancer Centre; Dijon Cedex France
| |
Collapse
|
18
|
Dialla PO, Dabakuyo TS, Marilier S, Gentil J, Roignot P, Darut-Jouve A, Poillot ML, Quipourt V, Arveux P. Population-based study of breast cancer in older women: prognostic factors of relative survival and predictors of treatment. BMC Cancer 2012; 12:472. [PMID: 23066863 PMCID: PMC3517437 DOI: 10.1186/1471-2407-12-472] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2012] [Accepted: 10/09/2012] [Indexed: 02/04/2023] Open
Abstract
Background A large proportion of women with breast cancer (BC) are elderly. However, there is a lack of information regarding BC prognostic factors and care in this population. The aims of this study were to assess the prognostic factors of relative survival (RS) among women with BC aged ≥ 75 years old and to identify the predictive factors of treatments administered to this population. Methods A population-based study was performed using data from the Cote d’Or breast and gynaecological cancer registry. Women aged 75 years and older with primary invasive BC and resident in Cote d’Or at the time of diagnosis made between January 1998 and December 2008 were retrospectively selected. Prognostic factors of RS were estimated in a generalized linear model with a Poisson error structure. RS rate for the whole population was given at 5 years. Logistic regression models were used to identify the predictors of the treatments administered. Results Six hundred and eighty-one women were included. Median age at diagnosis was 80. Comorbidities (p=0.02), pT stage (p=0.04), metastases (p=<0.001), having a family doctor (p=0.03) and hormone-receptor status (p=0.006) were independent prognostic factors of RS. The RS rate at 5 years for the whole population was 78.2%, 95%CI = [72.2-83.0]. Age, pT stage, metastases, histoprognostic SBR grade, hormone receptor status and comorbidities were frequently found to be predictors of treatment with surgery alone, hormone therapy alone, breast conserving surgery plus adjuvant therapy and mastectomy plus adjuvant therapy. Conclusions Comorbid conditions adversely affect survival in older women with breast cancer. Moreover the results of this study showed that there are numerous predictors of the type of treatment administered, and that the most important were age and comorbidities.
Collapse
Affiliation(s)
- Pegdwende Olivia Dialla
- Breast and Gynaecologic Cancer Registry of Cote d'Or, Centre Georges François Leclerc, 1 rue Professeur Marion BP 77980, Dijon Cedex 21079, France
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Ngo Quy C, Haller MA, Darut-Jouve A, Jolimoy G, Spaëth D, Beckendorf V, Bazarbachi T, Luporsi E, Coudert B, Martinet Y. Early whole brain concomitant radiotherapy-chemotherapy for non-small cell lung cancer (NSCLC) brain metastases. A phase 2 study. Lung Cancer 2000. [DOI: 10.1016/s0169-5002(00)80330-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
20
|
Coudert B, Lizard S, Arnal M, Genne P, Darut-Jouve A, Bélichard C, Arnould L, Riedinger J, Mayer F, de Gislain C, Fargeat P. Role of Mdr phenotype in locally advanced breast cancer (LABC) treated with primary chemotherapy (CT1). Eur J Cancer 1999. [DOI: 10.1016/s0959-8049(99)81179-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
21
|
Ngo Quy C, Haller MA, Darut-Jouve A, Jolimoy G, Spaëth D, Beckendorf V, Coudert B, Martinet Y. Early whole brain concurrent radiotherapy chemotherapy for non-small cell lung cancer brain metastases. A phase II study. Lung Cancer 1999. [DOI: 10.1016/s0169-5002(99)90749-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
22
|
Darut-Jouve A, Coudert B, Jolimoy G, Belichard C, Arnoud L, Guerrin J. [Neoadjuvant chemotherapy FEC-HD in locally advanced breast cancer]. Bull Cancer 1999; 86:189-94. [PMID: 10066950] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
Abstract
The tolerance and the clinical and histological efficacy of a neoadjuvant chemotherapy FEC-HD including hematopoietic growth factors have been studied in 40 patients with stade II or III breast cancer between February 1991 and February 1997. Four courses were given, every 21 days, with 5-fluorouracil (750 mg/m2/day D1 to D4 by continuous infusion), epirubicin (35 mg/m2/day D2 to D4) and cyclophosphamide (400 mg/m2/day D2 to D4) with G-CSF (5 mug/kg/day D6 to D15). The surgery was performed 3 or 4 weeks after the end of the chemotherapy. All patients had radiotherapy. The neoadjuvant chemotherapy induced 37.5% CR, 45% PR, and 15% SD. In 40% of the patients, the surgery was conservative. An histological CR was obtained in 15% with no axillary involvement one time out of two. There was intraductal carcinoma without invasive carcinoma in 7.5%. There was no differences between the response of inflammatory and non inflammatory tumors. One hundred and fifty-eight courses have been delivered. A grade 3 or 4 leuconeutropenia, anemia and thrombopenia have been observed in respectively 34.6%, 6.3% and 8.8% of the courses. A grade 3 or 4 mucositis has been noticed in 2.5% of the courses. A febrile granulocytopenia has occurred in 3.8% of the courses. The median survival without metastatic progression was 48 months and the median overall survival was not achieved. In stade II and III breast cancer, neoadjuvant chemotherapy with FEC-HD obtains an important histological response with an acceptable toxicity. The role of the dose-intensity increase on survival remains to be determined.
Collapse
Affiliation(s)
- A Darut-Jouve
- Centre Georges-François-Leclerc, 1, rue du Professeur-Marion, 21034 Dijon
| | | | | | | | | | | |
Collapse
|